Podcasts about Gilead

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.The market never sleeps and neither do smart traders. In this video, we dive into live trading insights, proven strategies, and powerful tools designed to help you save time, make money, and trade with less risk. This isn't about hype or guessing games—it's about using OVTLYR's data-driven signals and trading systems to gain an edge in any market.We'll start by breaking down today's market trends, including why the 10 over the 20 and price over the 50 setup matters more than ever. You'll see how OVTLYR's Golden Ticket Trading Strategy works in real time, helping identify bullish and bearish momentum with precision. From breadth signals to fear and greed heatmaps, we cover exactly what the market is saying right now—and what that means for your next trade.In this session, we go beyond theory and look at real trades placed live in the OVTLYR Trading Room. You'll see exit strategies, risk management rules, and why sticking to a plan keeps traders ahead while others get hammered chasing dips. We also highlight second-chance signals and show how disciplined position sizing protects your account while keeping you in the game for the big wins.It's not just about charts—this is about trading with clarity. You'll see how traders are using OVTLYR to double portfolios, avoid massive losses by respecting exit rules, and take advantage of setups across names like Gilead, Etsy, SoFi, and Delta. The process is always the same: clear signals, tight risk control, and letting winners run while cutting losers short.By the end, you'll see why OVTLYR is more than just a tool—it's a complete trading framework. From sector signals to individual stock breakdowns, everything is designed to strip out noise and give you clarity. No more emotional trading, no more chasing headlines, just pure, proven setups you can act on with confidence.If you're serious about trading smarter and not harder, this is your edge. Watch the full breakdown, learn the rules, and see how OVTLYR's Nine System is transforming the way traders approach the market.Here's what we cover:➡️ Market trends and why the 10/20/50 setup matters➡️ Breadth signals and second-chance opportunities➡️ Exit rules that protect your account➡️ Real trades explained step by step➡️ How OVTLYR simplifies trading decisionsStart trading like the pros with OVTLYR. Subscribe for more live trading insights, proven strategies, and powerful breakdowns every week.Subscribe for more daily trading room recaps, market breakdowns, and step-by-step trade analysis to sharpen your edge and trade with confidence.Gain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today

Then Moses climbed Mount Nebo from the plains of Moab to the top of Pisgah, across from Jericho. There the Lord showed him the whole land—from Gilead to Dan, all of Naphtali, the territory of Ephraim and Manasseh, all the land of Judah as far as the Mediterranean Sea, the Negev and the whole region from the Valley of Jericho, the City of Palms, as far as Zoar. Then the Lord said to him, This is the land I promised on oath to Abraham, Isaac and Jacob when I said, I will give it to your descendants. I have let you see it with your eyes, but you will not cross over into it.Deuteronomy 34:1-4Hello everyone and welcome to the Christian Educational Ministries Weekend Bible Study. It is good to be with you and we thank you for being there and allowing us to make this weekly service possible.Tonight we are pleased to continue our study on the book of Deuteronomy, which teaches us to know God, love God and obey God. Filling in for Ronald L. Dart, with his conclusion of this fascinating series, is our good friend, Richard Crow.

This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Navigating Vaccine Hesitancy in Pediatrics Evaluation and Credit:   Navigating Vaccine Hesitancy in Pediatrics   Evaluation and Credit:  https://www.surveymonkey.com/r/medchat81 Target AudienceThis activity is targeted toward primary care physicians and advanced providers. Statement of Need Despite the availability of safe and effective vaccines, pediatricians and clinicians continue to encounter significant vaccine hesitancy among caregivers, which can lead to suboptimal immunization rates and increased risk of preventable diseases. This podcast will provide key information for providers on the causes of vaccine hesitancy and how to address with parents. In that it is a podcast, it will be a discussion with the guest and moderator. Objectives Define pediatric vaccine hesitancy and describe its impact on public health. Discuss key factors that contribute to vaccine hesitancy. Describe effective communication strategies to address parental concerns to improve vaccine confidence in pediatric care. ModeratorMark McDonald, M.D., MHA, CPE System Vice President Pediatric Medical Affairs Medical Director, Norton Children's Louisville, Kentucky SpeakerKristina Bryant, M.D. Pediatric Infectious Diseases Physician Norton Children's Infectious Diseases Chair, Norton Children's Hospital Infection Control Associate Fellowship Director Professor UofL School of Medicine Louisville, Kentucky Planner and Moderator Disclosures  The planners and moderator of this activity do not have any relevant financial relationships with ineligible companies to disclose. Speaker DisclosureThe speaker, Kristina Bryant, M.D. discloses relevant financial relationship with Sanofi as an investigator. She had relationships with Gilead, Enanta Pharmaceuticals and Pfizer as an investigator. These relationships have ended.  All relevant financial relationships have been successfully mitigated. Commercial Support  There was no commercial support for this activity.  GrantThis episode is supported by a grant from the Kentucky Medical Association's ‘Small STEPS, Big Impact' campaign, a two-year initiative that encourages patients to achieve long-term success through taking simple steps that can add up to make a big impact on their health. The campaign focuses on five key areas (screenings, tobacco use, exercise & nutrition, physician visits and stress) and offers straightforward strategies and support for patients. It is a partnership between the KMA and its charitable arm, the Kentucky Foundation for Medical, made possible by a grant from the Kentucky Department for Public Health. For more information, visit SmallSTEPSKy.org.     Physician Credits Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing CreditsNorton Healthcare Institute for Education and Development is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.75 ANCC CE contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.   For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org. Social Worker CreditsThe National Association of Social Workers, Kentucky Chapter (NASW-KY), is an approved provider for social work credits through the Kentucky Board of Social Work. This activity will provide 1.0 hours of required continuing education units. NASWKY # 0630/25.   Resources for Additional Study/References A Review of the Resurgence of Measles, a Vaccine-Preventable Disease, as Current Concerns Contrast with Past Hopes for Measles Elimination https://pubmed.ncbi.nlm.nih.gov/38525549/ A Structural Lens Approach to Vaccine Hesitancy and Identity https://pubmed.ncbi.nlm.nih.gov/36841595/ SmallSTEPSKy.org   Date of Original Release | Aug. 2025; Information is current as of the time of recording.  Course Termination Date | Aug. 2027 Contact Information | Center for Continuing Medical EducationNavigating Vaccine Hesitancy in Pediatrics; (502) 446-5955 or cme@nortonhealthcare.org   Also listen to Norton Healthcare's podcast Stronger After Stroke. This podcast, produced by the Norton Neuroscience Institute, discusses difficult topics, answers frequently asked questions and provides survivor stories that provide hope.   Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.  

TWiV discusses the latest worrisome Executive Order on oversight of federal grantmaking, RFK Jr winds down mRNA viral vaccine development, Lenacapavir, a drug for AIDS prevention and treatment, and how respiratory virus infections awaken dormant metastatic breast cancer cells in lungs. Hosts: Vincent Racaniello, Alan Dove, Rich Condit and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Oversight of Federal grantmaking (Whitehouse.gov) Grantmaking gets a Christofascist (Rasmussen Retorts) HHS winds down mRNA vaccine development (HHS) Lives saved by COVID vaccines (JAMA) Lenacapavir review (Bicochem Pharm) UNAIDS urges Gilead to lower price of lenacapavir (UNAIDS) Gilead and price gouging (Wikipedia) Respiratory virus infections awaken metastatic breast cancer (Nature) Letters read on TWiV 1243 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Xkcd: Geologic Periods Rich – Old Man's War by John Scalzi Alan – The Broken Earth trilogy by N. K. Jemisin Vincent – Cacio e pepe: Good Food pasta recipe sparks fury in Italy Listener Pick Linda – DNA captured in air could identify life forms Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Der Blick richtet sich zum Wochenausklang vor allem auf die seit gestern Abend gemeldeten Ergebnisse. Akamai, Block, Gilead, Expedia, Instacart und Monster Beverage profitieren teils stärker von den soliden Ergebnissen und teils angehobenen Aussichten. Trade Desk und Sweetgreen werden nach den Zahlen vorbörslich förmlich hingerichtet, mit den Aktien von Pinterest und Microchip ebenfalls unter Druck. Die Aktien von Taiwan Semiconductor dürften von den robusten Juli-Verkaufszahlen profitieren, die über Nacht gemeldet wurden. Ein so großes Intraday-Reversal wie gestern, ist ein kurzfristig für gewöhnlich negatives Signal. In Anbetracht der nahenden Juli-Verbraucherpreise, die vor dem Opening am Dienstag gemeldet werden, könnten wir Zurückhaltung und Gewinnmitnahmen sehen. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

Werbung | Exklusives Angebot für unsere Hörer: Lest das Handelsblatt 12 Monate zum halben Preis: www.handelsblatt.com/sommerrabatt Der Blick richtet sich zum Wochenausklang vor allem auf die seit gestern Abend gemeldeten Ergebnisse. Akamai, Block, Gilead, Expedia, Instacart und Monster Beverage profitieren teils stärker von den soliden Ergebnissen und teils angehobenen Aussichten. Trade Desk und Sweetgreen werden nach den Zahlen vorbörslich förmlich hingerichtet, mit den Aktien von Pinterest und Microchip ebenfalls unter Druck. Die Aktien von Taiwan Semiconductor dürften von den robusten Juli-Verkaufszahlen profitieren, die über Nacht gemeldet wurden. Ein so großes Intraday-Reversal wie gestern, ist ein kurzfristig für gewöhnlich negatives Signal. In Anbetracht der nahenden Juli-Verbraucherpreise, die vor dem Opening am Dienstag gemeldet werden, könnten wir Zurückhaltung und Gewinnmitnahmen sehen. Ein Podcast - featured by Handelsblatt. +++Erhalte einen exklusiven 15% Rabatt auf Saily eSIM Datentarife! Lade die Saily-App herunter und benutze den Code wallstreet beim Bezahlen: https://saily.com/wallstreet +++ +++EXKLUSIVER NordVPN Deal ➼ https://nordvpn.com/Wallstreet Jetzt risikofrei testen mit einer 30-Tage-Geld-zurück-Garantie!+++ +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html

Join Washington Examiner Senior Writer David Harsanyi and Federalist Editor-In-Chief Mollie Hemingway as they discuss the Department of Justice's decision to move forward with a grand jury investigation of key Russiagate players, review an update on the congressional Jeffrey Epstein probe, and analyze Texas Democrats' response to the state redistricting battle. Mollie and David also share their thoughts on the Pee-wee Herman documentary, House of David, Chief of War, The Naked Gun, and the book Gilead.If you care about combating the corrupt media that continue to inflict devastating damage, please give a gift to help The Federalist do the real journalism America needs.

Join Washington Examiner Senior Writer David Harsanyi and Federalist Editor-In-Chief Mollie Hemingway as they discuss the Department of Justice's decision to move forward with a grand jury investigation of key Russiagate players, review an update on the congressional Jeffrey Epstein probe, and analyze Texas Democrats' response to the state redistricting battle. Mollie and David also share their thoughts on the Pee-wee Herman documentary, House of David, Chief of War, The Naked Gun, and the book Gilead.If you care about combating the corrupt media that continue to inflict devastating damage, please give a gift to help The Federalist do the real journalism America needs.

There was also a lot for the tribe of Manasseh; for he was the firstborn of Joseph; to wit, for Machir the firstborn of Manasseh, the father of Gilead: because he was a man of war, therefore he had Gilead and Bashan.JOS.17:2 There was also a lot for the rest of the children of Manasseh by their families; for the children of Abiezer, and for the children of Helek, and for the children of Asriel, and for the children of Shechem, and for the children of Hepher, and for the children of Shemida: these were the male children of Manasseh the son of Joseph by their families.JOS.17:3 But Zelophehad, the son of Hepher, the son of Gilead, the son of Machir, the son of Manasseh, had no sons, but daughters: and these are the names of his daughters, Mahlah, and Noah, Hoglah, Milcah, and Tirzah.JOS.17:4 And they came near before Eleazar the priest, and before Joshua the son of Nun, and before the princes, saying, The LORD commanded Moses to give us an inheritance among our brethren. Therefore according to the commandment of the LORD he gave them an inheritance among the brethren of their father.JOS.17:5 And there fell ten portions to Manasseh, beside the land of Gilead and Bashan, which were on the other side Jordan;JOS.17:6 Because the daughters of Manasseh had an inheritance among his sons: and the rest of Manasseh's sons had the land of Gilead.JOS.17:7 And the coast of Manasseh was from Asher to Michmethah, that lieth before Shechem; and the border went along on the right hand unto the inhabitants of Entappuah.JOS.17:8 Now Manasseh had the land of Tappuah: but Tappuah on the border of Manasseh belonged to the children of Ephraim;JOS.17:9 And the coast descended unto the river Kanah, southward of the river: these cities of Ephraim are among the cities of Manasseh: the coast of Manasseh also was on the north side of the river, and the outgoings of it were at the sea:JOS.17:10 Southward it was Ephraim's, and northward it was Manasseh's, and the sea is his border; and they met together in Asher on the north, and in Issachar on the east.JOS.17:11 And Manasseh had in Issachar and in Asher Bethshean and her towns, and Ibleam and her towns, and the inhabitants of Dor and her towns, and the inhabitants of Endor and her towns, and the inhabitants of Taanach and her towns, and the inhabitants of Megiddo and her towns, even three countries.JOS.17:12 Yet the children of Manasseh could not drive out the inhabitants of those cities; but the Canaanites would dwell in that land.JOS.17:13 Yet it came to pass, when the children of Israel were waxen strong, that they put the Canaanites to tribute, but did not utterly drive them out.JOS.17:14 And the children of Joseph spake unto Joshua, saying, Why hast thou given me but one lot and one portion to inherit, seeing I am a great people, forasmuch as the LORD hath blessed me hitherto?JOS.17:15 And Joshua answered them, If thou be a great people, then get thee up to the wood country, and cut down for thyself there in the land of the Perizzites and of the giants, if mount Ephraim be too narrow for thee.JOS.17:16 And the children of Joseph said, The hill is not enough for us: and all the Canaanites that dwell in the land of the valley have chariots of iron, both they who are of Bethshean and her towns, and they who are of the valley of Jezreel.JOS.17:17 And Joshua spake unto the house of Joseph, even to Ephraim and to Manasseh, saying, Thou art a great people, and hast great power: thou shalt not have one lot only:JOS.17:18 But the mountain shall be thine; for it is a wood, and thou shalt cut it down: and the outgoings of it shall be thine: for thou shalt drive out the Canaanites, though they have iron chariots, and though they be strong.

Host: Emer Joyce Guest: Christian Hassager Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1812?resource=interview  Want to watch the full episode? Go to: https://esc365.escardio.org/event/1812   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers:  Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

EPISODE 142 | Project 2025: The First 180 Days (World Is Weird 15) Donald Trump said he didn't really know much about Project 2025 except that they sure liked him. And yet, of 313 specific Project 2025 initiatives, he's already enacted 108 of them, and another 63 are actively in the works as of this recording. Quite a coincidence, wouldn't you say? Project 2025 put a lot of importance of a sort of blitzkrieg if their boy won the 2024 election, a flurry of activity to define the first 180 days of his presidency and hopefully create so much change that, no matter what happens in future elections (if there are any) many of the changes they want to see happen will end up sticking around. That benchmark date was July 19.  So, let's look at Project 2025. What they say, and some of their own justifications for why they say it. And we'll also see just how much Trump has actively assisted them in realizing their vision for a very different America than the world has ever seen.  Like what we do? Then buy us a beer or three via our page on Buy Me a Coffee.  Review us here or on IMDb. And seriously, subscribe, will ya?  SECTIONS 02:40 - The Mandate for Leadership, Version IX - The first of the Four Pillars, "cultural Marxism"; yes, it really is Gilead; white nationalists and Christian nationalists, family is the key, four main goals 08:52 - Three More Pillars - Info gathering, the Presidential Administration Academy, "climate change" is code for Christian depopulation, a secret playbook, Carter was evil, the DoD and Space Force 13:16 - Economy - General ideas, "fair trade" vs. "free trade", the Consumer Protection Bureau, the Department of Labor, the Department of Commerce 21:05 - Environment - General ideas, the Environmental Protection Agency, the Department of the Interior 25:09 - Transportation - General ideas, get married and make babies or no funding, the Department of Transportation, the FAA 27:11 - Education - General ideas, education is a private good, not a public one; the Department of Education, Parental Bill of Rights 33:12 - Identity - General ideas, LGBTQ+ and trans people ("radical gender ideology"), DEI, pornography 36:15 - Journalism - General ideas, the Corporation for Public Broadcasting, the FCC, the US Agency for Global Media (now a One America News organ), the Open Technology Fund 38:39 - Healthcare - General ideas, Medicaid, Medicare, the Department of Veteran Affairs, the CDC, the Department of Health is really the Department of Life, marriage, abortions, Planned Parenthood, in vitro fertilization, teen pregnancy, the Department of Health and Human Services 47:43 - Legal - General ideas, affirmative action, the FBI, the death penalty, the Secret Service as military cops, the Department of Justice, FACE Act no longer enforced, don't say trans 53:16 - National Security - Foreign policy shifts, USAID, NATO, nukes, the Department of Defense, Cybercom, the State Department, strengthen ties with Saudi Arabia 57:26 - Immigration - CBP, ICE, TSA, USCIS, refugees, asylum pay-to-stay scheme, birthright citizenship, mass deportations, more police, FEMA funds, the Department of Homeland Security 01:04:42 - Elections - General ideas, the FEC gets limits, photo ID to vote, armed police at polling stations 01:06:58 - Expansion of the Executive - The President is boss, loyalists only, the Insurrection Act of 1807, more surveillance 01:09:24 - Federal Staffing - Bring back the spoils-and-patronage system, the White House, the National Security Council 01:12:01 - Final Thoughts - Trump totally knows about Project 2025, the vision for an America-that-never-was, why the hell didn't you vote? Music by Fanette Ronjat More Info Project 2025 Tracker website (updated daily) r/Keep_Track Full text of "Project 2025 Mandate For Leadership" The “Mandate for Leadership” Series Inside Project 2025's Secret Training Videos - video on ProPublica YouTube channel 5 Reasons Leftists HATE Project 2025 from the Heritage Foundation Project 2025 Quick Read

As we continue our study verse by verse through the book of Judges, we are introduced to a mighty warrior named Jephthah, a son of Gilead. The most striking feature of this portion of the story is the way in which it point us directly toward Christ, the Messiah. Scripture text is Judges 11:1-28.

About this episode: The United States stands at a pivotal juncture in eradicating HIV. Despite recent advancements, including the development of an effective new form of pre-exposure prophylaxis (PrEP), an uncertain future marked by cuts to Medicaid and research hurdles threatens to undo the country's progress. In this episode: Jeremiah Johnson, Executive Director of PrEP4All, sheds light on the urgent need for equitable access to PrEP and what's at stake if we fail to scale up initiatives to test, prevent, and treat HIV. Guest: Jeremiah Johnson is the Executive Director of PrEP4All—an organization that seeks to prevent the spread of HIV by identifying data-driven policy solutions to increase access to PrEP. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: Trump's Policies Could Undermine the Fight to End America's HIV Epidemic—Tradeoffs FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option—CNBC Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic—Journal of Law, Medicine & Ethics A National PrEP Program to End the Nation's HIV Epidemic—Public Health On Call (April 2022) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Jeff, Aunt Beth, and Jeff's mom Sue say hello (and goodbye) to Gilead one last time. Plus, those dang Emmy nominations are back at it again.Sue's Recommendations:-Sirens on Netflix-Stick on Apple TV+Beth's Recommendations:-The Gilded Age on HBO-The Bear on Hulu-Duster on HBO MaxWashington Black on HuluJeff's Recommendation:-The Blockbuster GameSubscribe to That's Auntertaiment!'s Patreon: https://www.patreon.com/thatsauntertainmentIntro and Outro Music from Bensound.comPlease leave us a review by heading to ratethispodcast.com/thatsauntertainment.Follow That's Auntertainment! on Twitter (@auntertainment), Instagram (thatsauntertainment), and Facebook (That's Auntertainment).Check out Jeff's blog at jmunney.comGot any questions or thoughts? Email us at thatsauntertainmentpodcast@gmail.com

Premier rapport, premières sensations, premières galères (ou pas) : dans cet épisode, avec mes 3 invités Benjamin, François et Martin, on parle découverte des préservatifs, anecdotes croustillantes, et souvenirs pas toujours glorieux…On se replonge dans leurs débuts, avec humour, sincérité et sans filtre. Egalement, ils répondent à un quizz Vrai ou WTF autour des préservatifs. On en profite pour tester la nouvelle innovation SKYN : les préservatifs Supreme Feel, sans latex et ultra sensoriels.Toluna – Harris interactive pour Gilead, enquête réalisée en ligne du 7 au 11 juin 2024 sur un échantillon de 2051 personnes représentatif de la population français âgée de 15 ans et plusDonnées chiffrés Supreme Feel :Plus extensible et 2x plus doux : Etude Lifestyles 2024, comparant SKYN Supreme Feel aux préservatifs sans latex naturel et synthétique.2x plus de chaleur : Etude Lifestyles 2024, comparant SKYN Supreme Feel à SKYN OriginalMentions légales relative au statut dispositif médical de Supreme Feel : Les dispositifs médicaux sont des produits de santé réglementés qui portent, au titre de cette réglementation, le marquage CE. Lire attentivement la notice. Demandez conseil à votre pharmacien. Il est rappelé l'intérêt des préservatifs dans la prévention du VIH / SIDA et des autres IST *** Partenariat commercial *** ** Infos **

Governor Josh Shapiro says he wants to be sure Pennsylvania plays a key role in developing artificial intelligence, as well as providing the energy needed to support it. Speaking at an energy and A-I summit in Pittsburgh this week, Shapiro said the state's skilled workforce and natural gas reserves helped attract a $20 billion dollar investment in new data centers recently pledged by Amazon. A number of large-scale data center projects were announced across the state including a $15 billion project planned for the Carlisle area, a $6 billion project in the Lancaster area and a $5 billion project planned for York County. A nonprofit group that helps unemployed people stay in their homes is calling for state property reassessment laws to be updated. The lawsuit could affect property owners across the state. Another attempt is being made to eliminate local property taxes in Pennsylvania: This latest effort, in the form of an amendment to the state Constitution, is co-sponsored by state Senator Doug Mastriano of Franklin County. It would prohibit school districts from collecting property taxes beginning July first, 2029 and require the General Assembly to come up with another funding method for public schools. Some state lawmakers are taking another shot at legalizing adult cannabis use in Pennsylvania. Senators Daniel Laughlin and Sharif Street, as well as Representatives Emily Kinkead and Abby Major introduced bipartisan recreational cannabis bills just four days apart. Both bills incentivize minority, women and veteran-owned small businesses to open dispensaries across the state. Pennsylvania is one of 49 states sharing in a 20 million dollar settlement with drug maker Gilead Sciences. It stems from a lawsuit which accused Gilead of illegally providing financial and other incentives to medical personnel in exchange for promoting and prescribing its HIV medications. Danville-based Geisinger is eliminating nearly 100 Geisinger Health Plan positions as part of an "operational restructuring" amid financial challenges that include a $231 million operating loss last year. Four independent voters in Pennsylvania are asking the state Supreme Court to rule that the closed primary system violates the state constitution. They filed a lawsuit arguing that keeping independents out of primaries effectively denies them the right to vote in many districts where primaries determine the outcome. The 260th York State Fair kicks off Friday. and runs through the following weekend until Sunday, July 27th. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

This episode covers: Cardiology This Week: A concise summary of recent studies ICD Indications in primary prevention Drug treatment of cardiac amyloidosis Mythbusters Host: Rick Grobbee Guests: Carlos Aguiar, Gerhard Hindricks, Marianna Fontana Want to watch that episode? Go to: https://esc365.escardio.org/event/1810   Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astrazeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Gerhard Hindricks Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1810?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Listener discretion advised. Today the girls will be exploring the haunting world of The Handmaid's tale. Join Nikki and Rachel as they discuss the devastating journey of June and her fight to be reunited with her daughter, Hannah. This show and episode is not an easy watch or listen, continue with caution. Follow the girls on Instagram:@two_girls_onereview

Pdm. Handoyo Salim (TB) Hakim-hakim 11 : 1Adapun Yefta, orang Gilead itu, adalah seorang pahlawan yang gagah perkasa, tetapi ia anak seorang perempuan sundal; ayah Yefta ialah Gilead.

Examining the history of nomadic pastoralism across Asia—from the Caucasus and Central Asian steppes to ancient Mesopotamia—reveals a consistent pattern: settled elites have repeatedly waged war against pastoral peoples. Both the Bible and the Qur'an emerged from nomadic pastoral societies, yet these same texts were later weaponized by sedentary civilizations against the very peoples once nurtured by them. We are witnessing this tragic pattern unfold again in real time—perhaps in its most brutal form yet—with escalating consequences that now reach into the heart of the West, the heir of Greco-Roman hubris.Even in pre-biblical East Asian traditions, such as the Confucian Book of Odes, herdsmen arrive with their flocks to establish an unnamed prince—a figure who emerges not from the city but from the periphery to usher in an era of divine justice. This archetype, consolidated in the Bible and the Qur'an, becomes active in the world whenever and wherever the voice from the pasture rises against the corruption of the palace.This is the Voice of the Scriptural God—The Voice of the Shepherd.It will not be silenced.It cannot be bought.It does not serve a throne.It does not belong to anyone.It roams freely upon the earth,calling its flock from the outlands, out of the city to the wilderness.The Biblical Jesus is near, habibi—And it's time for the Lord to act.It's time for Ibrahim's Discords.سُبْحَانَ مَنْ جَعَلَ فِي الْحَمْدِ نُورًا(subḥāna man jaʿala fī al-ḥamdi nūran)“Glory to the one who placed light within praise.”This week, I discuss Luke 8:32-34.Photo by Cajeo Zhang on UnsplashShow notesἀγέλη (agelē) / ע־ד־ר (ʿayin–dalet–resh) / غ–د–ر (ghayn–dāl–rāʾ)In the Gospel of Matthew, we are warned that God will separate the sheep from the goats. Mishearing this, the rule-followers among us foolishly turn their gaze outward, seeking to teach others which rules to follow. In doing so, they become goat-finders and goat-fixers—lions and bears who come not to protect the flock but to steal sheep from it.But in Luke's application of ע־ד־ר (ʿayin–dalet–resh) from the Song of Songs, this dichotomy is flipped on its head. When the mashal unfolds at the Decapolis in Luke, the Song's poetic use of ἀγέλη (agelē)—interchanging goats and sheep—reveals the Bible's mockery of human rule-followers. The constant switch between goats and sheep in the Song of Songs reflects a deliberate poetic symmetry: the goats evoke movement and allure (hair), while the sheep evoke purity and precision (teeth).This imagery, drawn from real pastoral life, is repurposed to undermine self-righteous Hellenistic legal constructs. There is no intent in the text to constrain the beloved or to define her by a boundary. Rather, it moves freely—dark and light, wild and ordered, descending and ascending—a complete pastoral image that cannot be systematized. The beloved is named not to be limited, but to be delighted in—not judged, but adored.David said to Saul, “Your servant was tending his father's flock [הָעֵדֶר (hā-ʿēder)], and when a lion or a bear came and took a sheep from the flock…” (1 Samuel 17:34)Know well the condition of your flocks [עֲדָרִים (ʿădārīm)], and pay attention to your herds; (Proverbs 27:23)Tell me, you whom my soul loves, where do you pasture your flock [עֵדֶר (ʿeder)], where do you have it lie down at noon? For why should I be like one who veils herself beside the flocks of your companions? (Song of Songs 1:7)Your hair is like a flock [כְּעֵדֶר (kə-ʿēder)] of goats, coming down from Mount Gilead. (Song of Songs 4:1)Your teeth are like a flock [כְּעֵדֶר (kə-ʿēder)] of newly shorn sheep, which have come up from their watering place… (Song of Songs 4:2)Your hair is like a flock [כְּעֵדֶר (kə-ʿēder)] of goats that have descended from Gilead. (Song of Songs 6:4)Your teeth are like a flock [כְּעֵדֶר (kə-ʿēder)] of ewes which have come up from their watering place… (Song of Songs 6:5)Still, even in the open pasture, there are rules of engagement. This is how one should hear the text—as a Bedouin.Surat Al-Anfāl (سورة الأنفال, The Spoils of War) addresses the terms of conflict and the proper conduct of the faithful toward their enemies. It contains the Qur'an's only occurrence of the Lukan-corresponding root غ–د–ر (ghayn–dāl–rāʾ)—a term that denotes treachery or betrayal. Even when nomadic clans behave treacherously, those who follow God are commanded to act transparently—even in the face of betrayal. The response to ghadr is not reciprocal deceit, but open disengagement.The verse also contains the word قَوْمٍ (qawm), meaning “those who stand or rise together as a group,” from the root ق–و–م (qāf–wāw–mīm). Its presence evokes the image of a herd rising for judgment—a disobedient gathering whose posture does not guarantee righteousness. Instead, it invokes divine judgment, alluding to the Day of the Lord. This imagery echoes the Gosp...

Title: Ordering With GodSeries: Prayer: Order a Disordered SoulText: 1 Kings 18:1-15Main Idea: Payer orders our hearts with God's presence.  - But how?Prayer together:Our Father in heaven, Hallowed be Your name. Your kingdom come. Your will be done On earth as it is in heaven.Give us this day our daily bread. And forgive us our debts, As we forgive our debtors.And do not lead us into temptation, But deliver us from the evil one.For Yours is the kingdom and the power and the glory forever. Amen.Priority1 Kings 16:30 Ahab son of Omri did more evil in the sight of the Lord than all who were before him. 31 As if following in the sinful footsteps of Jeroboam son of Nebat were not bad enough, he married Jezebel the daughter of King Ethbaal of the Sidonians.  Then he worshiped and bowed to Baal. 32 He set up an altar for Baal in the temple of Baal he had built in Samaria. 33 Ahab also made an Asherah pole; he did more to anger the Lord God of Israel than all the kings of Israel who were before him.1 Kings 17:1 Elijah the Tishbite, from Tishbe in Gilead, said to Ahab, “As certainly as the Lord God of Israel lives (whom I serve), there will be no dew or rain in the years ahead unless I give the command.”1. By becoming UNFAMILIAR with what is FAMILIARPerspective1 Kings 18: 7 As Obadiah was traveling along, Elijah met him. When he recognized him, he fell facedown to the ground and said, “Is it really you, my master, Elijah?” 8 He replied, “Yes, go and say to your master [AHAB], ‘Elijah is back.'” 9Obadiah said, “What sin have I committed that you are ready to hand your servant over to Ahab for execution? 10 As certainly as the Lord your God lives, my master has sent to every nation and kingdom in an effort to find you. When they say, ‘He's not here,' he makes them swear an oath that they could not find you. 11 Now you say, ‘Go and say to your master, “Elijah is back.”' 12 But when I leave you, the Lord's Spirit will carry you away so I can't find you. If I go tell Ahab I've seen you, he won't be able to find you and he will kill me. That would not be fair, because your servant has been a loyal follower of the Lord from my youth. 2. By SEEING more than DOINGPower1 Kings 18:15 But Elijah said, “As certainly as the Lord of Heaven's Armies lives (whom I serve), I will make an appearance before him today.”3. By being RIGHTEOUSLY CONFRONTATIONALChallengeTRUST God with Your PRAYERS

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people aged 50-59 who are at risk of severe disease, following recommendations from ACIP members he had previously fired. Biogen CEO Chris Viehbacher tried to strike a deal with Sage as the company searched for a way forward after setbacks, but Sage was not interested. In other news, late-stage stumble for Cosentyx sets Novartis back in autoimmune conditions, and Gilead eyes HIV market domination with a twice-yearly treatment. Additional stories include biotech leaders and investors urging the FDA to maintain access to Mifepristone, Regeneron scoring a nod for a bispecific drug for multiple myeloma, and the increasing demand for bioinformatics roles in the industry.

Howie and Harlan discuss the alarming healthcare cuts proposed in the budget bill currently moving through Congress, recent breakthroughs in HIV prevention and diabetes treatment, and the stark contrast between scientific progress and the deep structural flaws in the U.S. healthcare system. Links: The Budget Bill H.R.1—119th Congress (2025-2026) “A List of Nearly Everything in the Senate G.O.P. Bill, and How Much It Would Cost or Save” “Senate passes Trump's tax-cut bill that would slash Medicaid spending” “5 ways Trump's tax bill will limit health care access” “Murkowski Casts Decisive Vote for G.O.P. Policy Bill, Making an ‘Agonizing' Choice” “Mapping Hospital Employment By State” “Health Care Just Became the U.S.'s Largest Employer” The Budget Bill and Universities Yale Office of the Provost: “Actions in anticipation of federal legislation” “Yale pauses hiring, tightens budget in anticipation of endowment tax hike” “Yale Is Rushing to Sell Billions in Private Equity Investments” “Trump Has Targeted These Universities. Why?” “Republican Plan to Tax Elite Colleges Could Hit in Unexpected Places” “The NIH's drastic cut to indirect cost rates is a critical threat to U.S. research infrastructure” The 340B Drug Program Congressional Research Service: Overview of the 340B Drug Discount Program “J&J suffers a loss over 340B drug discount program” “ Beyond the Sloganeering—A Data-Driven Analysis of Recent 340B Growth” American Hospital Association: Fact Sheet: The 340B Drug Pricing Program PhRMA: The 340B Hospital Markup Program A Stem Cell Treatment for Diabetes “Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin” “Kennedy Says ‘Charlatans' Are No Reason to Block Unproven Stem Cell Treatments” Mayo Clinic: “Stem cells: What they are and what they do” Cleveland Clinic: Diabetes “Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes” Medicare Advantage and the VA “Insurers Collected Billions From Medicare for Veterans Who Cost Them Almost Nothing” “Lawmakers Seek to Close VA Loophole That Funnels Billions to Private Medicare Insurers” “Medicare Advantage Plans With High Numbers Of Veterans: Enrollment, Utilization, And Potential Wasteful Spending” A New HIV Drug HIV.gov: A Timeline of HIV and AIDS “HIV protection with just two shots a year: FDA approves Gilead drug” “Shuttering of USAID Will Lead to Millions of Deaths Around the World: Studies” “Evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030: a retrospective impact evaluation and forecasting analysis” Kennedy v. Braidwood Health & Veritas Episode 84: Abbe Gluck: The Legal Determinants of Health Supreme Court opinion: KENNEDY, SECRETARY OF HEALTH AND HUMAN SERVICES, ET AL. v. BRAIDWOOD MANAGEMENT, INC., ET AL. “Kennedy v. Braidwood: The Supreme Court Upheld ACA Preventive Services but That's Not the End of the Story” “Supreme Court Upholds Preventive Services Requirement Under ACA” The Big Picture for U.S. Healthcare “The Perfect Storm has Hit U.S. Healthcare” “National Health Expenditure Projections, 2024–33: Despite Insurance Coverage Declines, Health To Grow As Share Of GDP” Exercise and Cancer “Structured Exercise after Adjuvant Chemotherapy for Colon Cancer” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Host: Perry Elliott Guest: Karim Lekadir Want to watch that episode? Go to: https://esc365.escardio.org/event/1808?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson."

This episode covers: Cardiology This Week: A concise summary of recent studies Big data in cardiology Measuring lipids: what clinicians need to know Milestones Host: Perry Elliott Guests: Carlos Aguiar, Karim Lekadir, Kostas Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/1808 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Kostas Koskinas has declared to have potential conflicts of interest to report: speaker fees / honoraria from MSD, Daiichi-Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. A judge has suspended mass layoffs at the Department of Health and Human Services, ruling that the staff cuts are likely unlawful as the agency does not have the authority to make such changes without Congress. In other news, private equity firms have recently acquired Bluebird Bio, a gene therapy biotech company, raising questions about their motivations. Additionally, RFK Jr. is advocating for changes to the vaccine injury compensation program to include COVID-19 vaccines, while the FDA is considering regulatory action on Argenx's Vyvgart Hytrulo due to safety concerns. The article also discusses Gilead's plans for dominance in the HIV market with a new drug, and other updates in the pharmaceutical industry.Private equity firms are increasingly targeting biotech companies, with Bluebird Bio recently being acquired by two firms. The first half of the year saw a surge in M&A activity in the pharmaceutical industry, with big pharmas like Eli Lilly and Novartis making multiple deals. Deals related to Alzheimer's disease also saw a significant increase following the approval of new treatments. Gilead is expanding its presence in the HIV market with a new drug, while GSK is also vying for market dominance. Other notable deals include AbbVie's acquisition of Capstan and Novartis' partnership for cardiovascular disease targets. Overall, the industry is seeing increased activity and interest from private equity firms and big pharma companies.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The Supreme Court ruled in favor of Gilead in an HIV prevention case, leaving decisions on coverage of the pre-exposure prophylaxis drug to a task force led by RFK Jr. A depression drug missed its phase II endpoint but showed positive signals in other areas. The ACIP committee is scrutinizing the safety of mRNA vaccines, while analysts are focusing on safety data presented by Novo, Lilly, and Amgen at the American Diabetes Association meeting.In other news, the FDA blocked an accelerated path for a Becker muscular dystrophy drug, Altimmune's stock dropped due to mixed mid-stage data, and Calico entered into an aging research deal with Mabwell. ACIP also voted to remove thimerosal from all flu vaccines, and former regulators expressed concerns about the integrity of the FDA approval process. These updates cover a range of developments in the pharmaceutical industry, shedding light on key advancements and challenges within the healthcare sector.

Grace never lowers the standards of holiness. Jesus didn't lower the bar, He raised it. Bible in a Year: Job 8-16 & Acts 9:23-34 

In reading our text you have learned that there is a balm in Gilead, that there is a great physician there; He has checcked your fearful, mortal malady, and you shall live forever. Bible in a Year: Job 5-7 & Acts 8:1-25 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC's new vaccine advisors are meeting with an unexpected agenda today, including discussions on topics such as Sanofi and Gilead's protein degrader deals, the FDA's review of Sarepta's gene therapy, and a contentious hearing with RFK Jr. over vaccines. The meeting marks the beginning of a new era for the influential vaccine committee. The FDA has named a psychedelic proponent as CDER deputy director, while Nektar has declared a Phase IIb win for eczema treatment. Experts say conflicts of interest among axed ACIP members are a "red herring," and the pharma industry is facing turmoil in failed immuno-oncology projects. Prescription drug sales are projected to hit $1.75 trillion by 2030, thanks to GLP-1s. Transitioning to the next news, a major pharmaceutical company has announced a breakthrough in cancer research, potentially changing the landscape of treatment options for patients worldwide. This development comes at a time when the industry is seeing significant advancements in personalized medicine and targeted therapies. Moving on to regulatory updates, the FDA has recently approved a new drug for a rare disease, providing hope for patients who previously had limited treatment options. This decision showcases the agency's commitment to expediting the approval process for innovative therapies that address unmet medical needs. In other news, a biotech startup has secured funding for its groundbreaking technology that aims to revolutionize drug delivery methods. This investment highlights the growing interest in novel approaches to drug development and underscores the importance of innovation in the industry.Wrapping up today's episode, we take a look at the latest trends in digital health, with companies leveraging artificial intelligence and big data analytics to improve patient outcomes and streamline healthcare delivery. These technological advancements have the potential to transform the way healthcare is delivered and pave the way for a more efficient and patient-centric system. That's all for today's episode of Pharma and Biotech daily. Stay tuned for more updates on the latest developments in the pharmaceutical and biotechnology sectors.

In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more. •    Intro :58 •    The interview/about Regueiro 1:03 •    Tell us about your family and where you grew up. 1:24 •    How did you get interested in medicine? 2:16 •    Who were your early influences?  4:18 •    What is the medical home? 5:57 •    How did you develop the idea to apply the medical home model to IBD? 7:45 •    Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57 •    Why hasn't this model become standard of care for patients with complex IBD? 14:13 •    What has worked, and what hasn't worked when it comes to adopting an integrative care medical home model? 18:15 •    Are there themes patients share as to why they wouldn't want to be enrolled in a medical home? 21:28 •    What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09 •    What have you learned in this position at Cleveland Clinic? 25:23 •    Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34 •    How would you recommend that people prepare for having a position like this? 27:34 •    Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02 •    With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06 •    What are the challenges that you still see in the ways we are using telehealth? 39:05 •    What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26 •    Thank you, Miguel 42:55 •    Thanks for listening 45:11 Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Regueiro, follow @MRegueiroMD on X. Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC.

Navigating the growing complexity of bladder cancer care is essential to improving patient access and treatment closer to home. In this episode, CANCER BUZZ speaks with Suzanne Merrill, MD, urologic oncologist at Colorado Urology about barriers and solutions to delivering high-quality bladder cancer care in community settings. CANCER BUZZ also speaks with Patrick Hensley, MD, urologist at University of Kentucky Markey Cancer Center, about implementing the Delivering High-Quality Bladder Cancer Care infographic in the community setting. Created by ACCC and BCAN, the infographic describes the 10 elements of excellent bladder cancer care. Cancer programs that align their practices with these guidelines can join a public registry so that patients and caregivers can identify quality bladder cancer care close to where they live. “The best strategies and tools to deliver high quality bladder cancer care out in the community lie first and foremost with having a bladder cancer clinician. It could be a urologist, it could be a urologic oncologist, could even be a medical oncologist or a radiation oncologist...their discipline doesn't matter as much as [having] the core clinical expert that is excited and dedicated to developing and instituting a comprehensive bladder cancer program.” - Suzanne Merrill, MD, FACS “Everybody assumes comprehensive care is being delivered at academic university settings, which it is, but there's so much...bladder cancer care being performed out in the community. So [the question is] how can we achieve comprehensive programs out in the community?” - Suzanne Merril, MD, FACS “I think it's really important that subspecialists and community providers work together to streamline those referrals and anticipate when the patients are coming in and what their needs are going to be, from a procedural standpoint, imaging standpoint, etc, so that you can avoid some of those undue delays in diagnosis and treatment.” - Patrick Hensley, MD Suzanne Merrill, MD, FACS Urologic Oncologist Colorado Urology Aurora, CO Patrick Hensley, MD Urologist Markey Cancer Center – Urology University of Kentucky Lexington, KY   Resources: Infographic: Delivering High Quality Cancer Care in the Community Addressing Disparities in Bladder Cancer Care Understanding and Mitigating Disparities in Bladder Cancer Care Bladder Cancer Advocacy Network (BCAN)   Funder Statement This program is supported by Astellas Pfizer Alliance, EMD Serano, and Gilead.

Let the insults begin! This month's JW Broadcast features the graduation ceremony for the 157th Class of Gilead, including the latest installment of their talk show and one, would be king, confessing that some Jehovah's Witnesses are really annoying.  TWITTER: @exjwpodcastINSTAGRAM: survivingparadisepodcast

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

In reading the Old Testament you will learn that there is a balm in Gilead, In reading the New Testament you will learn that the balm is Jesus., Bible in a Year: Esther 1-2 & Acts 5:1-21 Gpys 

Host: Susanna Price Guest: Sabiha Gati Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1809?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1809   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease risk: Framingham Heart Study insights Sudden death in female athletes Mythbusters: Owning a pet reduces the risk of heart disease Host: Susanna Price Guests: Carlos Aguiar, Sabiha Gati, Vasan Ramachandran Want to watch that episode? Go to: https://esc365.escardio.org/event/1809 Want to watch that extended interview on sudden death in athletes? Go to: https://esc365.escardio.org/event/1809?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. The ESC is not liable for any translated content of this video.The English-language always prevails. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel, Susanna Price and Vasan Ramachandran have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

BOOK OF JUDGES Wounded Leaders 6.15.25 Judges 11:1-3 Now Jephthah the Gileadite was a mighty warrior, but he was the son of a prostitute. Gilead was the father of Jephthah. 2 And Gilead's wife also bore him sons. And when his wife's sons grew up, they drove Jephthah out and said to him, “You shall not have an inheritance in our father's house, for you are the son of another woman.” 3 Then Jephthah fled from his brothers and lived in the land of Tob, and worthless fellows collected around Jephthah and went out with him. Judges 11:29-33 Then the Spirit of the Lord was upon Jephthah, and he passed through Gilead and Manasseh and passed on to Mizpah of Gilead, and from Mizpah of Gilead he passed on to the Ammonites. 30 And Jephthah made a vow to the Lord and said, “If you will give the Ammonites into my hand, 31 then whatever comes out from the doors of my house to meet me when I return in peace from the Ammonites shall be the Lord's, and I will offer it up for a burnt offering.” 32 So Jephthah crossed over to the Ammonites to fight against them, and the Lord gave them into his hand. 33 And he struck them from Aroer to the neighborhood of Minnith, twenty cities, and as far as Abel-keramim, with a great blow. So the Ammonites were subdued before the people of Israel. Judges 11:34-35 Then Jephthah came to his home at Mizpah. And behold, his daughter came out to meet him with tambourines and with dances. She was his only child; besides her he had neither son nor daughter. 35 And as soon as he saw her, he tore his clothes and said, “Alas, my daughter! You have brought me very low, and you have become the cause of great trouble to me. For I have opened my mouth to the Lord, and I cannot take back my vow.” Passion or zeal for God, if not rooted in the truth of God's character and the authority of Scripture, can lead to disastrous outcomes. Jephthah reasons with God like a warrior, not a worshipper. Jephthah shows us the consequences of operating in our own wisdom and strength rather than trusting God's character and faithfulness. When a leader carries deep insecurities and unhealed hurt, that pain doesn't remain internal. It leaks into their decisions, relationships, and the culture they create. God's Spirit may empower someone, but that doesn't mean all their actions are good or Spirit-led.

Dr. William Soliman is the founder and CEO of the Accreditation Council for Medical Affairs (ACMA). The ACMA is America's leader in life sciences accreditation, certification & training.  Soliman is a former pharmaceutical executive who worked in leadership roles at Merck, Abbvie, Gilead and more. He is considered a pharma industry futurist and has been featured on NewsNation, Fox News, Newsmax, Forbes, Al Jazeera, Yahoo Business TV, ABC News Radio & more. The ACMA established the first ever certification standards in the United States and stands as a benchmark of excellence for prior authorization professionals, reimbursement professionals, pharmaceutical sales professionals, medical science liaisons and medical affairs professionals.  Dr. Soliman received his PhD from Columbia University & his BA from New York University.

We asked chatGPT,  "Why does it seem like the united states government is against its citizens today?" Here is what the magic 8 ball delivered: https://chatgpt.com/share/682df261-24d4-8012-8a17-a681a60869edInteresting! Because at some point we were not able to inquire! and speaking of not trusting our government: Vietnam War RecommendationsThe Women: Kristin Hannah https://www.goodreads.com/book/show/127305853-the-womenTurning Point Vietnam War: https://slate.com/news-and-politics/2025/04/netflix-vietnam-documentary-turning-point-accuracy.htmlAdriana Smith You and your family are in our thoughts. https://www.tiktok.com/@momofboys211/photo/7505853436932525355South Sudan: https://abcnews.go.com/US/wireStory/judge-orders-us-officials-court-answer-questions-migrants-122028875Support the showThe Parlour with Lori and Lisa comes to you with our takes on current events, politics, human interest stories, all things close to our hearts, and so much MORE! Thank you for following our media journey and be sure to look for us as we roll out in all the social platforms. #SlowMedia

In this Bible Story, the great reign of David came to a close. Now Solomon rules over Israel with wisdom, mercy, and justice. As his first act as king, Solomon takes care of those who were loyal to his father, and deals justly with those who betrayed him. This story is inspired by 1 Kings 2. Go to BibleinaYear.com and learn the Bible in a Year.Today's Bible verse is 1 Kings 2:45 from the King James Version.Episode 113: As David is dying, he calls in his son Solomon to bless him and speak God's promises over him. David instructs him on what he should do with Joab and Shimei and requests that he show kindness to Barzillai of Gilead. But Adonijah was not done trying for the throne. He made a request of Bathsheba that Solomon rightly discerned as a claim to the throne. And so as per their agreement, he was executed. Solomon sought to rule his kingdom in fairness and enacted punishments that showed mercy to those who deserved death.Hear the Bible come to life as Pastor Jack Graham leads you through the official BibleinaYear.com podcast. This Biblical Audio Experience will help you master wisdom from the world's greatest book. In each episode, you will learn to apply Biblical principles to everyday life. Now understanding the Bible is easier than ever before; enjoy a cinematic audio experience full of inspirational storytelling, orchestral music, and profound commentary from world-renowned Pastor Jack Graham.Also, you can download the Pray.com app for more Christian content, including, Daily Prayers, Inspirational Testimonies, and Bedtime Bible Stories.Visit JackGraham.org for more resources on how to tap into God's power for successful Christian living.Pray.com is the digital destination of faith. With over 5,000 daily prayers, meditations, bedtime stories, and cinematic stories inspired by the Bible, the Pray.com app has everything you need to keep your focus on the Lord. Make Prayer a priority and download the #1 App for Prayer and Sleep today in the Apple app store or Google Play store.Executive Producers: Steve Gatena & Max BardProducer: Ben GammonHosted by: Pastor Jack GrahamMusic by: Andrew Morgan SmithBible Story narration by: Todd HaberkornSee omnystudio.com/listener for privacy information.

In this week's episode we're back with our recaps of The Handmaid's Tale. In its final season, we will recap each and every episode. This week we are recapping episode 609 and 610 of the series. Based on the best-selling novel by Margaret Atwood, this series is set in Gilead, a totalitarian society in what used to be part of the United States. Gilead is ruled by a fundamentalist regime that treats women as property of the state, and is faced with environmental disasters and a plummeting birth rate. In a desperate attempt to repopulate a devastated world, the few remaining fertile women are forced into sexual servitude. One of these women, Offred, is determined to survive the terrifying world she lives in, and find the daughter that was taken from her.              Host: Angelica Monk and Stacey Yvonne Music by: Sammus Edited by: Jamie Broadnax

Lez Hang Out is proud to be sponsored by Olivia, the travel company for lesbians and all LGBTQ+ women! Join our Patreon to unlock 25+ full-length bonus episodes (including our brand new one on Bros), ad-free weekly episodes, mp3 downloads of our original songs, exclusive Discord access, and more! Right now, we're retiring our lower tiers– so all new patrons who join at $5/month or higher (or upgrade!) by July 1st, 2025 will be entered into a raffle to guest star on a bonus Patreon episode. You can also support the show by grabbing your #pride gear at bit.ly/lezmerch & picking up Lez-ssentials songs on Bandcamp. Welcome back to Lez Hang Out, the podcast that wants to wish everyone a Happy Pride Month, because queer joy is resistance.  This week, Leigh (@lshfoster) and Ellie (@elliebrigida) hang out with Jennie Wetter, the Director of rePROS Fight Back (@reprosfb), an initiative that fights for sexual and reproductive health rights and justice issues. Jennie is also the creator and host of the rePROs Fight Back podcast. Among the many things that rePROS does to fight back is to grade each of the 50 states on access to reproductive and sexual health rights and care (including access to gender-affirming care). They have recently released their 13th annual (fully interactive!) 50-state Report Card and spoiler alert: The United States as a whole gets an F. Fair warning, looking up your state's grade might make your heart hurt (unless you're like Leigh and live in one of the 5 states that actually got an A).  We talk with Jennie about what things have been like for rePROS since the reversal of Roe and whether our Gilead robes absolutely have to be red (it's just not our color). Although it can be really easy to become overwhelmed by how bad things are, Jennie explains that there's actually a lot to be hopeful about. Between the abortion funds and local clinics there are quite a lot of resources on the ground to help people access care, even in states with strict legislation. Medication abortion remains available and is a fully safe option. With the recent attacks on trans rights, initiatives like rePROS are fighting even harder to ensure access to gender affirming care for all who need it, including minors. Even though at the federal level, things are bleak (that report card is a real eye-opener), there are ways to fight back at the state-level and getting involved locally can really help keep that feeling of doom at bay.  Jennie reminds us that no one person can do or know everything (even if Ellie's ADHD really wants her to try). Figure out which one cause you want to put your energy toward and focus solely on that. Even Jennie doesn't know everything, but she makes herself a trusted resource by knowing what direction to point people in when they come to her for help. Take a deep breath and remember, you don't have to take on everything yourself! Find your lane and follow it and know that others are doing the same in the lanes you didn't choose. Burning yourself out trying to do it all won't help anyone and certainly won't help you feel any better. We see you, we appreciate you, and we want you to remember: no act of resistance is too small.  Give us your own answers to our Q & Gay on Instagram and follow along on Facebook, TikTok, and BlueSky @lezhangoutpod. Find your fav tol and smol hosts Ellie & Leigh at @elliebrigida and @lshfoster. Learn more about your ad choices. Visit megaphone.fm/adchoices

A dying preacher writes a (rather) long letter to his son. Another dying preacher's son returns home, seeking…something. Salvation? Forgiveness? A balm? Robinson's novel is a deeply considered portrait of a family of ministers, wrestling with the powers and limitations of their faith and fatherhood.This episode is sponsored by Squarespace. Go to squarespace.com/overdue for 10% of your first purchase of a website or domain.Our theme music was composed by Nick Lerangis.Follow @overduepod on Instagram and BlueskyAdvertise on OverdueSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jacob escapes with his family, crossing into Gilead while Laban gives chase. When he catches up, accusations fly, but Laban fails to prove that anyone in Jacob's camp stole his household gods. With no evidence and mounting tension, the two men draw a line in the sand—literally—by forging a covenant of peace. This treaty, sealed with a meal and an oath, marks a turning point as Jacob steps further into the promises of God.  Rev. Craig Wehmeyer, pastor of Immanuel Lutheran Church in Washington, MO, joins the Rev. Dr. Phil Booe to study Genesis 31:21-55.  To learn more about Immanuel Lutheran, visit IMLutheran.org. Genesis isn't just the start of the Bible; it's the foundation of everything. Creation, sin, judgment, grace, covenant, and promise all take root in this remarkable book. The stories are ancient, but their truths are eternal. In this new series from Thy Strong Word, Pastor Phil Booe and his guests walk verse by verse through Genesis, exploring how God reveals Himself as Creator, Judge, and Redeemer. From the grandeur of the cosmos to the struggles of ordinary families, Genesis introduces us to a God who speaks, acts, and keeps His promises. So, whether you've read it a hundred times or are just now cracking it open for a serious look, this series will help you see Genesis with fresh eyes—and a deeper faith. Thy Strong Word, hosted by Rev. Dr. Phil Booe, pastor of St. John Lutheran Church of Luverne, MN, reveals the light of our salvation in Christ through study of God's Word, breaking our darkness with His redeeming light. Each weekday, two pastors fix our eyes on Jesus by considering Holy Scripture, verse by verse, in order to be strengthened in the Word and be equipped to faithfully serve in our daily vocations. Submit comments or questions to: thystrongword@kfuo.org.

In a world competing for our attention, our guest this week admits: “It's probably harder to read novels now than it ever was.” But their value cannot be overstated. The novel's unique humanity, its careful and open treatment of the human experience, helps us to develop a sympathetic imagination, tuning our hearts and minds in a way that non-fiction argument simply cannot. Christopher Scalia, author of 13 Novels Conservatives Will Love (but Probably Haven't Read), makes the case that it is a distinctly conservative interest to explore the Western tradition through fiction. Recommendations in hand, he invites adults to refresh their reading list with novels—from the very inception of the form up to the present. Chapters: 1:47 The great book rut 4:11 Novels: the medium of recent Western tradition 5:30 The 18th-century bildungsroman 9:47 “Conservative” themes 16:18 The American dream in My Ántonia 22:39 Miraculous realism in Peace Like a River 29:02 Acknowledging the existence of evil 31:44 Wonder and encounter over strict interpretation 37:03 Revisiting works from your school years 38:47 Why narrative works 42:01 Books that nearly made the cut Links: 13 Novels Conservatives Will Love (but Probably Haven't Read) by Christopher Scalia Christopher J. Scalia at American Enterprise Institute The History of Rasselas by Samuel Johnson (1759) Evelina by Frances Burney (1778) Waverley by Sir Walter Scott (1814) The Blithedale Romance by Nathaniel Hawthorne (1852) Daniel Deronda by George Eliot (1876) My Ántonia by Willa Cather (1918) Their Eyes Were Watching God by Zora Neale Hurston (1937) The Girls of Slender Means by Muriel Spark (1963) The Children of Men by P. D. James (1992) Peace Like a River by Leif Enger (2001) Gilead by Marilynne Robinson (2004) The Road by Cormac McCarthy (2006) How I Won a Nobel Prize: A Novel by Julius Taranto (2023) Also on the Forum: Heights Forum Book Reviews On Reading Literature by Joseph Bissex Some Summer Reading Recommendations for Teachers by Tom Cox Modern Literature: On Curating the Contemporary featuring Mike Ortiz Guiding Our Boys through Modern Literature featuring Joe Breslin and Lionel Yaceczko Featured opportunities: Teaching Essentials Workshop at The Heights School (June 16-20, 2025) Convivium for Teaching Men at The Heights School (November 13-15, 2025)